Involving a sponsored research contract with Mount Sinai School of Medicine, VentriNova, had been a startup based around the work of Icahn School of Medicine at Mount Sinai regenerative medicine director. The effort iseems to have been to attempt to develop a gene therapy procedure that would help regenerate cardiomyocytes, or muscle cells, in the hearts of patients who have suffered heart attacks. VentriNova, Inc. is developing small molecules and gene therapies that stimulate heart cells to reenter the cell cycle, therefore regenerating lost heart tissue. VentriNovas lead product targets the Cyclin-A2 gene to induce cellular proliferation of cardiomyocyte, and is in the preclinical stage of development.
